Reports & Insights | Pharma Contract Manufacturing

This exclusive interview with Philip Coetzee, Director of CMO Management at Daiichi Sankyo, provides a strategic look at the contract manufacturing landscape ahead of the Pharma Contract Manufacturing Summit 2025. With the market facing major shifts due to acquisitions and divestitures, Philip Coetzee shares his perspective on:

• Industry Consolidation: Understand how recent high-profile acquisitions and divestitures are reshaping choices for pharma companies in the CMO market.
• Opportunities for Independent CMOs: Explore how independent CMOs can leverage new collaborative platforms to offer specialised services and gain market share.
• Navigating Market Uncertainty: Learn how pharma companies can address partnership challenges with CMOs in a consolidating market.
• Emerging Trends: Gain insights into the future of contract manufacturing, including the role of niche service providers in a rapidly evolving ecosystem.

Whether you’re a pharma executive, CMO leader, or industry consultant, this interview offers valuable takeaways on navigating industry consolidation, balancing flexibility with control, and identifying growth opportunities in the evolving contract manufacturing landscape.

This insightful interview with Sam Badawy, Quality Assurance Manager at Bayer, offers a comprehensive look at the challenges and strategies in maintaining quality assurance within pharma contract manufacturing. As regulatory landscapes shift and digital transformation accelerates, Sam Badawy discusses key strategies for building resilient CMO partnerships, including:

• Building Trust and Communication: Understand the importance of clear communication and trust to manage compliance and quality across diverse regions.
• Navigating Regulatory Changes: Learn how Bayer’s quality teams stay proactive amidst evolving regulatory requirements to prevent compliance issues.
• Balancing Sustainability and Quality: Discover how Bayer integrates sustainability goals within CMO partnerships to reduce environmental impact without compromising quality.
• Leveraging Digital Tools: Evaluate the role of AI, data analytics, and automation in enhancing quality monitoring and ensuring consistent standards.
• Future Trends in Quality Management: Gain insights into how digital transformation and sustainability will shape the future of quality assurance in pharma.

For professionals in pharmaceutical quality assurance and manufacturing, this interview provides actionable insights into managing complex CMO partnerships, and examines approaches to compliance, sustainability, and digital innovation to stay competitive in an evolving industry.

This exclusive interview with Dr. Ulrich Rümenapp, Senior Biotech Program Lead at Bayer AG, delves into the key strategies for biotech manufacturing success. With biotech manufacturing facing new challenges and opportunities, Dr. Rümenapp covers essential topics, including:

• Prioritising Quality in Biotech Manufacturing: Learn how to integratequality assurance and quality control from the earliest stages of product development to ensure safety and compliance.
• Top Dos and Don’ts for Biotech Partnerships: Explore Dr. Rümenapp’s recommendations for pharma companies deciding between in-house manufacturing and external partnerships.
• Balancing Cost, Control, and Scalability: Understand the full cost of ownership and the value of flexibility when making critical manufacturing decisions.
• Future-Proofing Biotech Manufacturing: Discover Dr. Rümenapp’s advice for maintaining adaptability in the face of rapid technological advancements.
• Leveraging Specialised Expertise in Partnerships: Learn the importance of maintaining internal capabilities while partnering with CMOs that offer specialised knowledge in areas like gene editing.

For pharma professionals involved in biotech manufacturing, this interview offers actionable insights on balancing quality, cost, and control. Gain expert perspectives on how to leverage specialised partnerships, maintain compliance, and navigate the complexities of biotech production for future-ready manufacturing strategies.

Ahead of the Pharma Contract Manufacturing 2025 Summit, discover expert insights from speakers Kyriakos Kansos and George Ntortas of Fuliginous Management Consulting, on building effective pricing models for CDMO partnerships. This exclusive interview Pharma IQ explores key strategies for navigating pricing complexities, leveraging value-based approaches, and crafting risk-sharing agreements that drive profitability and strengthen collaborations. Download this exclusive content to gain expert advice on creating resilient and profitable pricing strategies for the CDMO market.

Key Takeaways Include:

• Understanding Pricing Models: Learn how to balance Cost-Plus, Market-Minus, and Benchmarking models to create a sustainable pricing framework.
• Value-Based Pricing: Explore how CDMOs can align pricing strategies with customer value and market expectations for mutual benefit.
• Crafting Risk-Sharing Agreements: Gain insights into structuring transparent agreements that balance investment, accountability, and collaboration.
• Leveraging Data Analytics: Discover how advanced data tools can refine pricing, track profitability, and optimise RFQ success rates.
• Future Trends in CDMO Pricing: Understand how emerging technologies and structured pricing models can support innovation-driven profitability. 
  

Explore effective strategies for successful CMO partnerships in pharma. Ahead of the upcoming Pharma Contract Manufacturing Summit, 26-27 March 2025, Pharma IQ spoke to Maik Talarczyk, Head PMO ESO at Sandoz, to discuss quality alignment, innovation, and future-proofing contract manufacturing partnerships in this exclusive interview.

Download this exclusive interview with Maik Talarcyzk, Head PMO ESO, from Sandoz to access:

• Insights into reducing complexity in CMO partnerships and streamlining operations.
• Essential practices for building strong, flexible relationships with CMOs.
• Common pitfalls to avoid in CMO collaborations and how to address them. - Strategies for aligning quality standards and integrating technology for transparency.
• Future-focused advice for resilience and innovation in CMO partnerships.
  

The Pharma Contract Manufacturing 2025 conference is dedicated to addressing the most critical challenges in the pharmaceutical manufacturing landscape, with a focus on fostering strong partnerships and operational excellence. This exclusive presentation from Pharma Contract Manufacturing 2024 explores key negotiation strategies tailored for the pharma industry, equipping professionals with the tools to enhance their contract manufacturing operations.

Delivered by Philip Coetzee, it combines practical insights and theoretical approaches to help stakeholders create effective, collaborative partnerships.

Key Takeaways:

• Foundational Principles: Understand the basics of effective negotiation, including trust-building, clarity in communication, and aligning expectations.
• Mental Preparedness: Learn how mindset plays a crucial role in negotiations, with techniques for building self-confidence and visualizing successful outcomes.
• Strategic Preparation: Discover how to plan, brief, execute, and debrief negotiations effectively, ensuring continuous improvement.
• Win-Win Outcomes: Explore the four possible outcomes of any negotiation and how to aim for mutual success.
• Practical Tools and Resources: Gain access to suggested courses, readings, and LinkedIn Learning recommendations to refine your negotiation skills further.

Why Download This Presentation:

• Gain actionable strategies for negotiating effectively with CMOs and CDMOs.
• Discover tips for preparing and executing negotiations under diverse cultural and operational conditions.
• Learn from real-world applications and expert insights tailored to the pharmaceutical sector.

Download this presentation to elevate your negotiation skills and build stronger, more productive partnerships in the pharma manufacturing industry.

The Pharma Contract Manufacturing 2025 conference will focus on fostering long-term, sustainable partnerships in the pharmaceutical manufacturing space. This presentation from 2024 provides key insights into harmonising processes, values, and goals between CMOs and their partners, addressing critical issues such as regulatory compliance, sustainability, and cost management.

The importance of selecting the right CMO/CDMO partnership is critical, as the benefits go beyond significant cost reduction, there is also the potential to improve and develop more strategies for pharmaceutical companies. But only if a mutually collaborative, open and trusting relationship is built.

Ahead of the Pharma Contract Manufacturing Summit 2025, we spoke exclusively to Federica Fraschetti, Associate Director, Focus Factory Leader – Bio ExM, MSD about the key do’s and don’ts when selecting a CMO, to help you find the right fit for your pharmaceutical company.

Download the full article here >>>

When selecting partners, meeting stringent sustainability criteria along entire pharmaceutical supply chains has far-reaching environmental, economic and reputational benefits. Whilst adding a sustainability criteria to the bidding process is a positive one for driving more responsible operations across the entire pharmaceutical industry, it simultaneously amplifies the complexity of selecting a Contract Manufacturing Organization (CMO).

Unlock the report to delve into vital statistics and expert insights, covering:

• Stringent selection criteria: understand the pivotal role stringent criteria play in shaping responsible and sustainable partnerships
• Bottom line benefits: explore the tangible economic advantages that sustainable practices bring to the forefront of your pharmaceutical operations
• Technology for greener supply chains: navigate the latest innovations driving sustainability in pharmaceutical supply chains and stay ahead in the industry

Topped up with expert commentary from industry leaders: Philip Coetzee, Director CMO Management, Daiichi Sankyo and Gregory Vanderwinden, Associate Director – External Manufacturing EU, MSD.

Elevate your CMO selection process and lead the way towards a greener, more sustainable pharmaceutical future.  Access the report now.

Ahead of the Pharma Contract Manufacturing Summit 2023, Pharma IQ spoke exclusively to David Berry, Head of Digital Business Systems - Pharma, CPI about connecting automation to a QP dashboard at the MMIC, to help you discover new opportunities and solutions to your current pharma manufacturing challenges. 

Fill in the form below to access David's exclusive insights >>>

Pharma IQ surveyed over 50 industry professionals, and accompanied by commentary from Ulrich Ruemenapp, Head of Launch Preparation at Bayer, this report will take an in-depth look at the most important components when selecting a CMO, the greatest risks when choosing to outsource and best practises for managing CMO networks.

Download the full report now >>>

Additional benefits to downloading the full report:

• Discover where the industry is at in its Pharma outsourcing journey
• The important factors to consider when selecting a CMO
• Find out more about how to reduce your external partner footprint
• Industry results for the greatest risks of outsourcing 
• Learn more about the characteristics that are most valued in a CMO
• Professional opinions on what areas are missing from the CMO market

As pharmaceutical businesses worldwide become more aware of the importance of meeting sustainability goals, it is inevitable that this will become a consideration when selecting a contract manufacturing organisation (CMO) or contract development and manufacturing organisation (CDMO). But it’s important to ensure that meeting sustainability goals when collaborating with external partners is genuine rather than just greenwashing.

That's why ahead of Pharma Contract Manufacturing 2024 we have collated exclusive insights on CMO Selection - Making Sustainability a Top Priority.

Access the infographic and dive into:

• The Top 5 considerations for sustainable CMO selection
• Key questions for the selection process
• Changing the culture strategy
• Examining your Scope 3 emissions
• Real-world examples of setting measurable targets
• Looking ahead: The big picture benefits

Due to the pandemic, the medical needs of populations worldwide are increasing and there is a huge demand for pharmaceutical products, causing CMOs and CDMOs to be increasingly sought after by pharmaceutical companies for their specialist equipment, facilities, labour force and cost-effective production. However, as large pharmaceutical companies start to develop in-house manufacturing capabilities, there is more and more competition between CMOs and CDMOs to prove they are the best partner.

Ahead of this year's Pharma Contract Manufacturing 2022 event, we spoke to Ulrich Rümenapp, Head of Launch Preparation and Coordination at Bayer AG, about the importance of maintaining positive partnerships with CMOs and CDMOs, to help you create and maintain positive partnerships with your CMOs and CDMOs, and build industry resilience.

Download the full interview now >>

Additional benefits to downloading the full interview:

• Discover how the last 18 months has impacted CMO and/or CDMO partnerships
• Learn about the greatest challenges of complex product manufacturing, and the top tips for overcoming these challenges
• Find out more about the benefits and opportunities of CMO and/or CDMO partnerships
• A summary of the key initiatives for maintaining positive CMO and/or CDMO partnerships over the next 2 years

It’s hardly surprising that pharma companies are changing the way they work with external partners, with increasing pressures on quality, cost and scalability determining not only which manufacturers the industry outsources to, but how many partners to take on.

With this in mind, Pharma IQ spoke with Simon Hendry, BD Director, Adare Pharmaceuticals, on the current challenges and best practices of streamlining external networks of CMOs. Hendry, speaks in-depth on the critical success factors you need to uncover in the selection process and how to manage emerging markets, all whilst ensuring quality isn’t compromised.

Download the full interview on the right >>

Other key benefits to downloading the full interview:

• Analysing what changes need to be made over the next 12-24 months to meet the main challenges of the industry
• Understanding the best practices for building a successful CMO partnership
• Exploring what criteria is most valuable to the industry when selecting a CDMO
  

Interested in seeing who you will meet at Pharma Contract Manufacturing 2025? Download our 2025 attendee list to see who is joining us so far! At the event, we will bring industry leaders, experts, and innovators together from the CMO/CDMO and pharmaceutical industry, to engage in meaningful discussions and share best practices to tackle the challenges of today.

Present your boss with this customizable letter detailing the reasons why you should attend Pharma Contract Manufacturing 2025 from 26th - 27th March 2025, in Berlin, Germany. Just download the letter template below, adjust as necessary (or edit as needed) and submit! We hope to welcome you there!